Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial

INTRODUCTION: Pateclizumab (MLTA3698A) is a humanized mAb against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis. This study was conducted to assess the safety, tolerability, < NOTE: For...

Descripción completa

Detalles Bibliográficos
Autores principales: Emu, Brinda, Luca, Diana, Offutt, Carolyn, Grogan, Jane L, Rojkovich, Bernadette, Williams, Marna B, Tang, Meina T, Xiao, Jim, Lee, June H, Davis, John C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392792/
https://www.ncbi.nlm.nih.gov/pubmed/22225620
http://dx.doi.org/10.1186/ar3554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392792/
https://www.ncbi.nlm.nih.gov/pubmed/22225620
http://dx.doi.org/10.1186/ar3554

Ejemplares similares